Yes, and program concentration is structural in aerospace rather than a management failure. Buyers price it by modeling the platform's remaining production life and rate, so the honest schedule is what protects the valuation.
More detail
Build the schedule before you go to market: each platform, your position and part numbers, the rate history, the published or expected production outlook, your share, and the competitive situation. Then be explicit about what diversification exists, including approvals that let you quote work you have not yet won. Buyers who are active in aerospace are comfortable with concentration they can model and uncomfortable with concentration that is presented vaguely. Where the platform is mature and rates are declining, the realistic conversation is about the value of the approvals and the capacity rather than the current revenue, and there are buyers specifically looking for approved capacity to feed with their own programs.